EY What Europe Has To Offer Biotechnology Companies

What Europe has to
offer biotechnology
companies

and regulatory framework
Contents
Foreword 3
Executive summary 4
Introduction 7
Biotechnology regulatory overview 11
Part A: The establishment of a company:

a country-by-country overview of
start-up considerations 20
Part B: Key tax considerations through the

biotechnology life cycle 70
Part C: An industry study and the outlook

for biotechnology in Europe 76
Acknowledgements 86
Glossary of terms 88
What Europe has to offer biotechnology companies

1
2
Foreword
by Máire Geoghegan-Quinn,
European Commissioner for
Research, Innovation and Science

;

9

"

"
!
<4 44
"

#$

"
4
% &'

(
)*

9

+, -+,.
= 3

,+

4574

'

% +
6;
>
"

6 * ?

9

,+

;
*

'

/
! " #$
%

+, "
+,

*

$

0
"
1

2 $
3
*
04545 6 2

457894545
% +
:Innovating for
Growth: A Bioeconomy for Europe 0
7

%

(@@@ @ @@457454A

A A

4
%
% 9 4545

3
Executive
summary
B

$

3

What Europe has to offer biotechnology

and regulatory framework 3
#$
% "

'

-">. 2
3
;

9 0
-+,.

*

'

" 04545

6
% +
; >

*

4
Horizon 2020
;

6
* *

1

9
9

4574 6
+ 9
* ? ;
=

$ 3

+

;

B
,+

"

+,

"

-C#?.*
C#?

'
- "2
= .

+,

/ 3
"
9

%3 /

' '

"

1

+,:

3
C#?+

D

=
"
75974E

+

Neil Byrne Thomas Saylor Nathalie Moll Stephan Kuhn

Global Life Sciences EuropaBio Chair of Secretary General Area Tax Leader

Tax Leader the SME Platform EuropaBio - EMEIA


5
6
Introduction
* +
4545

*

=

,+
+,

2

9

+

2
*

9

,

2

%

leading role in the growth agenda of the next
"
2

4555+,

*

=
9

9

9

-C#?.

+

+,


7

+,
3

,
C ;

,

* =
=

=
Ź Agricultural biotechnology
2!

>
!>F
0
*
=!
4545

,+

+,

B
,

*

*
=
+ =
*

-

.
H
9 =,; %

9 H

'

H

G

H6
+,

* 3
H

'
*
H
3

+, 1

1 ,+ *
%

0

(
*

%

Ź Healthcare biotechnology ,+

+,
C#?
+

+
9

D

+

- ?B; D
D

?B; "

D

?B;=

.
B

Ź Industrial biotechnology0 %
9

9
9
*

+,
*

- 3

."

8
" *

0

+, 9

9

1
9 +,"

-.

+, :

0
,+

" : 3

9 =

"
3

;

9

*

*
G

9

,+

+,
+

2


9
10
Biotechnology
regulatory
overview
Outline of regulatory

"

framework for (bio-) 4OE
pharmaceutical products 457K7OE 4575*

6;GC
in the European Union 7E98E

B ;
Pharmaceutical Industry explained
* >

*

C#?

-
.
4

*

C#?
*
0C#?
-
9

. 0 ;
",+
;
-

0 .

I

* 9

= :
:

9 "

*

8

*

Legislative overview
IE 4575"
;

(
7
:
;-;.
Ź B ; :IJE
:
Ź :4JE * (
Ź ; ; ; :7KE Ź ' 0

6
Ź L:77E
0-6
Ź M ; :NE 0 .D
G Ź '

0

-6;GC.IE9NE
,+
457797K
- 0
3

*

,+.D
7
" 4KL4577
4
+#>2&"+ (> )4L45777I
I
"
8
"

11
Ź ' 0
6 , > ->;C.

K

0 -6,>.%
6,>2
*
0

0 "
; 6,>
-+>6.

/- @
!
6 " , /.
0*
+ >

6

0

0
+ 0,;6
6,>

6 1 , >

?B;
-61,>. 6 ;
N
* * -6;*.

0 2
* 0
475
455K

; 4575 6,> 6,>

4558*

7NF

0

*

0

, ;
-,;. = =
KJ69 -

0
=
= O 6,> 0
6,>.
778
*

;
0
*

2@ * 0 6,>

,;2
9
0
,+ ,;
Table 1: Product approvals by EMA, 2000 – 2011
F
=
6
=
Total approvals Generics Biosimilar
J
2011 FF 4N 5
"455K+,1 ,;
2010 K5 44 7 9 9 0
2009 75J 87 4

0
2008 K7 N I
0

6

2007 NK I K 75

+,
2006 IN 5 4
2005 7J 5 5 D
2004 I8 5 5 D
,; D
2003 78 5 5

2002 I5 5 5
2001 I8 5 5
;
0

2000 4F 5 5 3

K
B P4;D>
D6 7(,
; DB455K
N
+C
-6.BF4N@4558
6
, ;

F
+ ,;
O
,;4575;
J
*

?C;MQ; ( (@@@
12
= Outline of regulatory 4577: 45E
7774

*
9 0 = framework for agricultural

biotech products in the

9

European Union +44

0

Agricultural biotechnology explained
0
*

*
'

;
OE 4577M
6
,;6 : >
C 7N5 +

;6 ->C;6.: 7NF
%

6,> OE

=

4575"4577 7N

'

0" 9

"14577

+,
;

7I
45K5;

6 4577

3

<75
614 =
<OO 4575*

*
+ 9
an urgent need in Europe for appropriate

4558
<4O

1 4J

*
45777J

9

75 0 " 9 0

C/ -9.-.

6 " %0

;
+ ; 6

*
4577 85E 2

"

0 ( 9
0 +

4577(+ >

60 C G+
C >+*

-G,. 0
J7N8I778N5F
75

9 0 -+,.
-6.BF4N@4558
+,; (
77
C
-.B74IK@4575

C
-6.BF4N@4558
6

, ;
C
-6.B7IJ8@455F

74
? 4575@O8@

? 4557@OI@6 6

7I


13
**
Table 2: Global area of biotech crops in 2011: by country (million hectares) Legislative overview
Rank Country Area Biotech crops
G ,
(Million hecatres) 1
-G,1.
7JJ5*

*
1 +; NJ5 , 0 3 (

=
2 %0
*
I5I + 0
7 ,

*
D
3 ;
4IF + 0
4 "
*
75N 6 4

* G,
5 6 758 6 0

* G,1

6 6
*
IJ 6 4555

7 >

*
4O + 0(
*
8 > 4N 6 G,
9 + ;
*
4I , 0 without prior EU approval, whether for
*

10 Uruguay 7I + 0
G,
G,*
*
11 Bolivia 5J +
0
*
12 ; 5F 6

13 >
*
5N , 0 9
* - ? 4557@7O@
14 , 5I 6
6.
G,
*
15 % ! 5I 6
C
7O4J@455I
*
16 , 54 6 ? 4557@7O@6

17 +
*
57 , 0

18 6 V57 6
,+
19 6 V57 , 0 %
20 V57 , 0

-
21 >
V57 , 0 ;"? 4577@7O@6.
9

22 60 C V57 , 0
23 > V57 , 0 *

G,1(
24 Egypt V57 , 0
25 + V57 , 0 7C 99
99

26 Romania V57 , 0
=

27 + V57 > -? 4557@7O@6
28 6C V57 6 C
7O4J@455I
29 Germany V57 >
G,.
Total 4' !+;

-!+;.
Y7F
9

K5555
YYC
+(6 L4577
14
6 *

= 9
? <F<7K C
-6.B7O4J@455I
7F
? * 3 C
-6.B7OI5@455I
6
An overview of agbiotech legislation

+
6

,+ Ź ? 4557@7O@6
78
G,1

I>9
* ?

? 4557@7O@6C
-6.
*

G,1 B7OI5@455I

6
C
-6.B7O4J@455I*
! 7K
-? J5@445@6 .
0
5JEG,1G,19
G,1
G,1
8*

*
G,1"
0 =
75=
9
" 9

2
G, * ? C

99
7I
*
* 99
,+

*
!
'*1
G,1 C

- 9 0 C
7OI5@455I
9 . 9 0

9
G,1@G,1
B6
>% Ź *
G,1 @

G,1
How long do applications take and

G,1 * G,

C
-6.B @
what do they cost?
7O4J@455I
5JE
"
7N
*

G,

3

" @
3 +

D D
G,1
G,1

"

3
'*1

C
-6.B7O4J@455I

; '*1

&)

G, Ź G,1 0
G,1 G,1
,+

? 4557@7O@6 0
78
? 3

7K
? 4557@7O@6 > 6 74, 4557

6
? J5@445@61 L 6 M75N7F845577
7N
6 ? J5@445@64I; 7JJ5

1 L 6 M77F7K:4F
7F
C
-6.B7O4J@455I > 6 44+455I
1 L 6 M4NO
7O75455I7:4I
7O
C
-6.B7OI5@455I > 6 44+455I

? 4557@7O@61 L 6 M4NO@487O75455I48

15
G,1 Ź C
6N7J@4577
7O
C
0
-6.B7O4J@455I; 09 9 0
Ź 6 C
-6.B
Z Z
-G,.
NK@4558
? 4557@7O@ L7K4577"

6C
-6.B7O4J@455I 2
=

9
"
;

? 4557@7O@6 G,1
; Outline of regulatory
,+ G,1) = )
0 !+;

7J framework for industrial

biotechnology in the
Ź 6 C
European Union
4558@FOF@6
C
-6.B7O4J@455I!+;

-

The bioeconomy explained
!+;

*

." <4
C
-6.B
C
45
44
7OI5@455I
C
6 = +,* & )
;
6
44
6 Table 3: The bioeconomy in the European Union
" Sector Annual turnover Employment Data source
G,1,+ (billion €) (thousands)

C
-6.B Food JNK 8855 6";;
7J8N@455I9
Agriculture IO7 74555 61>;961G6;

Paper/Pulp IFK 7O55 6>"
Forestry/Wood ind. 4NJ I555 6"9%1"+
1

Fisheries and I4 K55 6YYY
Aquaculture
* (
Bio-based industries
Ź 6 C
-6.B
Bio-chemicals and K5- Y. 7K5- Y. +?;; ?M
N87@4558
plastics !,[
C
-6.B 6!"6
7O4J@455I >
Enzymes 5O- Y. K- Y. ;B0
6

? @G
0 ?+,

Biofuels NYY 7K5 EBB, eBio

Total 2078 22,005

Y 455JYY 44 FF

YYY6!
6!>% +
?"++B7OI59J77J4575
7J
+1LM754F8455878947
45
6 C
-6.NK@455878L4558

= G,11LM757N74558K97
47
6 -4558.6 4558@FOF@6814558

C
-6.B7OI5@455I1 L MI8O7O:4N
44

16
Legislative overview Sales of Biotech products

2007: €48b (3.5% of total chemical sales)
"

2012: €135b (7.7% of total chemical sales)

C 2017: €340b (15.4% of total chemical sales)

9

G. Festel (EFIB 2009. Lisbon, October 2009: OECD workshop, Vienna, January 2010)
7JJ5

9
Biotech sales per segment 2007
1
0 6
(
?-16?.
755E\<8O

45I5

FKE
micro-organisms (GMMs) 7OFE

474E 4KIE
7KE

-* % ? 455J@87@6

45I5(

16?. 9
-G,,. K8E I75E 44KE 8OE
"

+
The Act Biotech sales per segment 2012
9 455F
<8O=IKE 755E\<7IK
455J@87@6 >
"4574 6 ,N455J
7OFE 7KE
<7IKFFE
4I5E 48JE

D457F 9

47
<I85
7K8E
;

Summary K8E 485E 4O5E 8OE

,+=

9
-G,,.

Biotech sales per segment 2017
= 755E\<I85
$
= 7OFE 7KE

"4574 * ? ( 45KE IIIE

6 % Ź G

+

=
;""; K8E 48OE 478E 8OE

Ź 6
G,,
*

;""6G,,
!>
;""% % +
C "

6 ;

!>F 04545 and the environment
Ź * G,,


17
Ź *

" 3
G,,
(
4

Ź ; 8K
? 4557@7O@6 =

G,1 4
3
6

I

=

?

=
0 *

8K

market
Ź ; J5
* G,, " 3

4

*
4 * ; ?

G,,
9 (
8K
Ź 67(B

7

" ,+
Ź 64(M 4
;I

Ź 6I(, I

Ź 68(
8
* G,,= 44

Key terms of the Act
G 9
( 9

'
@ D
(
=
Ź G
= ;"
>;

;P>;% Ź * = ;">%

6 !

7 Contained use( 9

=7 G,,

G,, 7

=
Accident(

G,,
= 0

4I
? 455J@87@6D 755N455JD 1 L1LM74K47K455J
18
% , Context
+ (
* ? ?
Ź ;
J5@47J@6"

?

Ź >

! ?
"

9

,+

*

?
* ,+

6 ,+

* 6

* 6

6
?


19
Part A:
*
(
99
9

Austria 21
Belgium 24
Denmark 29
France 31
Germany 34
Hungary 37
Ireland 39
Italy 42
The Netherlands 45
Norway 49
Poland 51
Portugal 54
Spain 57
Sweden 60
Switzerland 64
The United Kingdom 68
20
The entrepreneurial culture
*
; *

;

9
9
:&;%96)
0:

* 1
0
-
; % ;
-;%;D
. .
; 6 6-'[1D
7 ; ' -;'+D . ; % "

.
; -;%"D .
9

M + ; -M"+;. ;%;9" ;

"

M"+; ; ;

; "

"
;

>-<455555
9.+
-<7
.
Taxation

%% Corporate income tax
-%1% .
; ;

1

M"+;;
3

4KE
"
*

1

3

B
*
6M"+;

6

M + *M"+;

;

;
%;[%;+M
6 C
4 !
]

-!!GD -^'.

. 3 447E

10% -C#?. ; 2

, ;

"
Cash premium can be
claimed for R&D expenses

21
€200,000

45E NE

*
; 29
* C#?

*

-;

."
FKE

=
"; =

+4KE
<755555% ;

3

=
"
<7!
-
.

755E

0

-

; 7K*

9

C#? ;C#?

.
=

;
3 0 9
"

*

K5E

*
+ NE
ii. National dividend exemption/

"

0 International participation exemption

45E

0 ? ;
;

;

N 45 -

= .6

=
Landscape for investors ;

=

i. Tax groups 3
=
6 ;;
! 9=
-

.

;
*
2= 3 75E

2 ;
'

K5E ;
Incentives
755E
6 -
;
= .C#?=75E
6

" are tax exempt under the international
6
9 D

3

9 -
-&_
!
]

).
. 9
- .
= ; 9
9
* C#?;

22
€1,000,000 Maximum AWS start up loan

1
Regulatory environment

- .
3 6 and incentives
7KE
= C

?
iii. Advance ruling
%
"

+ 4577 '
-
* M;

@0.;'+9
9
0-

.%
,;

' <K5555 C;6+C

K5E >
*

,

* * G,1

0 N9J 6 G,16

M
2

Landscape for entrepreneurs

Structuring for the future
; 2 !
]

(
4575
5E %
- ;
K5E <7.C

;
=
;%96 ;
"
=
Finance

"

Austria Wirtschaftsservice (AWS) Availability of capital

% ; -

!
9

=
;'+
!G B .;

`>+
[" ;'+ 4
; =
M"+;&&M"+;+
)>+
:

: 0

M"+;-.

0
7K

=
6

;'+9 ?

3*
=
9 ;
<455555
=

=
*
9
*

?

9 = =

9
9 "4577;'+ -.; 2
M"+;+
- P

. 6 "
<K

9 <7 9

;

23
The entrepreneurial culture ,%
2

Belgium %

+
N5E
C#?
P
0

-. %

2

K559 !

+ ?
B%
"6

(
;29

Ź

; Ź /

%
=B;*1 Ź

0 Ź
%
7N
9 *
"
0

1
0 6 > %

?-16?.
> ";

0 2+ *
2
"1455O* % %

#$
"
", 4577
%

* "
%
'%' '%

<FK

%

? 9
%
;

!' !% % * 485
'
0

0
;
C#? % '

"

2 0"

16?

24
Taxation 7
*
- %

. 74 .;

75E
Corporate income tax
= ? C ? =
6 %
3 *=

"
B9
*
3 Neither a minimum holding period nor a

9

%
; =
(
%

"%

Ź 1
(IE
"
* Ź "
(KE
IIE -3
Ź 6 (OE74KE
" .
<I44KK5

Ź , = (75E45E
484KEI8KE =
Ź 1 = (
%

? C ? 75E7KE
JKE =

*
9
= %
%

-I8IKE 4574.
*
"
=
= - .
KE 3

* /

C ==
;%

9
=

3

* %

*

2
*
*
75E

1

;
<4K55555!

C#?
%

=- . * 399

%

*

*

;

*

* %

%

;
0 ;= F(7
7KE4KE

3
;

2 3

"

'

%
2-

=

;
-

75E
.

7
*
4574%


25
6.8%
Maximum effective tax rate under PID
;99= 7(7 ' =

9 "
3 = - .
=
- *
9

>"?
Tax incentives .
*

" =

i. Patent Income Deduction %

(or Patent Box) " O5E-3.

>"? ->"?.
O5E
=
%
,
"
%
%

B
Tax landscape for investors
*
NOE >"? ;

%
*
ii. Tax credit or deductions for R&D
B "?
; C#?- 9=
= %

*= -">. >
. =
"? ->"?.
= * 0%
2
C#?

-G;;>.
9 ;= ; =
&C#?
i. Principal companies
Belgium to promote the development of new
& %
9

;
%

;
>"?

( D
07L455F
-
.B D

=
=
D

*
D %

*
*
= -9
.
*

0 - 9

-
.! 4574
.;
7IKE-9 . 2
%
2

45KE- .
"
*

6

= &)-

09
.
6

9 *

" >"?

26
ii. Holding companies +=
%

and incentives

*
3
; Biotech for health care
-
J5 . 6
*
+
%

;

%
2

;OKE %

=

755E
"
D
*

9 0 " %
2
+3
! !;
,
=

9 >-!;,>.
JKE %

;
;

=

"'*-;
"

J5
+ *
. -
;* ,

>. 0
*

!%

6B%"1+
" ?
-
=

" %

%
.6
I5EO5E

*

9 9 % 755E %
455O-

F5E

+"%

.
= ?
-3 = . Availability of capital
* 0 ;
;
2"

+4575 4OE " %

%
3

D

2

%
Finance * %
G
=

P

! " *
%

>,P* /

+

* " ;

-*"B;.

! G 4575"
*

G 4FE G",P
-
0 Biotech for industrial use

%

%G",P 0
=.*

=

$


27
!

%

M

the development of energy generated from
;

*

9

=
"
"

- . ">

*

K55555I %

0C#?">

Biotech in agriculture
">- >"?
;
%
2

"! .* ">

0

= >"?
;

' "

C(

%
-
+.
">

+ ;

%

"
">
? -? 4558@8O@6.

" %

!

*

,

B"?>"? &)
;
%

28
? "?9

?[[FK5555-
<755555. %
K5E

"

*

??%
! ?

;
?

2
, ? ?[[47I"

0
*
- = ."
?

= ? BB

M> M
-%"*.

2 +
0

Taxation 9

Corporate tax
%"*
"
! 0 99
= 8(7*
9
-C#?.
-
3 .* =
3 6
7JOJ7JJK

0
!

"

?[[7
2
N5E 0
IKE

4574
? ?[[47I
3
M
0
Tax credit of
DKK1.25 million

29
Funding of up to
DKK750,000
%"*2 9 .!
O5E
= 75E
?[[47I
-3

0
. Tax landscape for entrepreneurs
"

Tax incentives ?2
"
?
*
75E
755E
26 G
C#? *;- .

"
=

2
4574
*
*

=

4KE
C#?
?[[74K Finance
4KEC#??[[K
> 3 9 Availability of capital
3 9
"?

"
*
C#?
;

?
75E
> -">.

* ?

B
-
">-

B .
30
400
Biotechnology companies
operating in France
The entrepreneurial culture <FNI555

! * 4I555

!"
4575 855

I88IE!

?I74577
?I5457I

<4K5 3

KE

N555 *
-C#?. IN7E
; F7 * 7KE-7KKE
!
IIE

7N4E

<4K5
1
?I74577?

* I5457I.

& )

N5

9

L74577
%455N455O

<7K

=

C#?455J4577
;

;
2&G2" )

!2

2
9
-">. =

* " !;
-"!;.

4557 9
0

* 9

!*
9

?

0 ,
9 9

0

Taxation
"

Corporate tax

* 0
! IIIIE; 9
JKE
IIE


31
M generally look for one or more of the IIIIE

( ;7KE
<7N5E !

1) R&D tax credits
3
M
-
!2 C#?
9

"
<7 = ">."
I5E-85EIKE
!"
!2 0 .
C#?
3-
!
C#?
99= "

.D 3
7K(7*
C#?
-
C#?

0.D
4KE3

*
-
+,.
<4
0 * ! 3
2 3

? 3 *
- .

I5E-
0C#?- -
2
. fundamental, applied or experimental C
; ^.*
C 3 .D- .
C#?
II7@IE-
3
.*

-
3+,
.C
9
!
6=

! * +
(

*
Indirect taxation
*

"! P;* 7JNE =

! =*
3

3 B
47EFE
! Tax landscape for investors

* !
Incentives C#?

"! 9 0

$
" -$".

2) Intellectual property
- .
!2
"> 0
%

32

0 !
$"D *
- . 7KE K5E & )

C#?

=

*

;

K5E

<755555

-B

.6

C#?
!

* $"3

M

C#?3 - .

-
!
2 ">
.B $"

C#?

%

"
$

" 6
*

">
B "

- .
>" - .

= $"6D- .
D- .
- .
4KE
Tax landscape for entrepreneurs

!

* 3

K5E -

30%

.
Tax credit on eligible R&D expenditure

33
G

!4574"

Germany

*

: %

G

0
C *
6 *
- .G9%
-
9 .
9* G

-
9 9
.
C C
G-
9 9
.: 4574>

;

!
C , -. Corporate tax and trade tax
, - 6
.G*"- -;
;G.

.
-G

99 c
G.
G

G-

G .3
* G -[] .

9 -G.

*

!
9 9
G
* % C
G9
6
7KE

9

9 ;KKE

7KO4KE*
Taxation

* G

-.

G ?

-&* ).

0%
Dividend withholding tax may be reduced to zero for
certain non-resident corporate shareholders
34
60%
Percentage of taxable income exceeding
€1m that can be offset against losses
FE7OE! !

Incentives
7L455O
*

3>

3 4KE9 "

DN4KE9

+

DKE9

39
D74KE9

3 C#?
C
0 *;
G*#"

* * &

* <7 )
9

!C#?

1N5E I5E
G!

<7

-.
C#?

;85E 0 -%"*?;.
3

-& ). %"*?;
3
*

0
! =

0

"G

<K77K55

G
* *

9 4KE
(
9
G
= Ź * ,

= than <ID G

=
Ź * -;GG.
"

!

K5E

! " ! C
G
I7?455J 9 +-&
):

0-

4NIFKE.
= 9
4KE ? G
'
9

G

G .D G

Ź * = G
=

4E =

!
&

= 7KE
)
-&).

755E
= !

35
€8b
Funding made available to biotechnology sector
under relevant Federal Government programs
9 - 9 0

.
9 3

6= ?

JKE

=

4KEFKE

!
B

* =
G

% * 6
Finance Structuring for the future
Availability of capital

* B C +
% "
45I5 C ! G G
>
G!

G 4575

G
!
?

<O
7
9 *

9

Rules and regulations
*

* C#?

=
3 3
G
*

3
%

G'
; C#?

C >

<KK* % 9

C *
6

M
@

3
GC#?
* 3 B
0 0
&* G%

+4577)

7
36

2

*

0
* K5E
B ?;
9
- . 9
Ź * 0 (

* B0 [j
0q
-

2=
"*;
"*;D
.

4577"
- 9

9= I(7.C

9 9 0
0 "*;

, B
Ź *
(

Taxation

Corporate tax

;
9
7JE
B 75E
!K55-<7F.

Incentives
;2
;29
!(

Ź 6
9( -C#?.
0C#?%

C#?
=K5E 2 ;
* C#? 0
C#? -
9
0

3 .
-
C#?
" C#? 3
9 .

K5E

" 0

C#?
10%

!K5-<7F5555.*
K5E
C#?
Ź C (

-
Corporate tax rate
K5E 9 .

37
70% Percentage of FDI into
Hungary from the EU
Development tax allowance Finance

; ;

9

*
;
K5E
C#? :

* : " 9LC,"
!755-<IK5555.* K5E

75 +,2 *
2 * "*
O5E

(
" +0s >
VIP cash grant:
+,
Local business tax

Ź

Ź * C#? ;
, B

D
-!?".

<NIN-L4574."4575!?"
Ź 3
4575<7FJK

<I55 *
*

C#?3D
G
4577

Ź <75 <I, /

"
Development tax allowances: ;

F5E 3
-75E7JE. Ź 3 D
44EG

Ź

" Structuring for the future

EU cash grant programs:

G
Ź

D +

Ź
"
IKE

Tax landscape for entrepreneurs !7-<I8.D

Ź C#? -

.D

Ź 8KE

*

C#?
0
6

!K55-<7F.
C#?* K5E
-& ).

Availability of capital

C#? *
09

C#?

7JE
2

38
12,5%
Ireland’s corporate tax rate
The entrepreneurial culture 9
" "

0

'

*

<85555

->C+".

*
"3 74KE *

, ;

*

?
"
"2 4KE -C#?.

IFKE

C#? *
*

9

" =
* -">.;

IK
" %;+"+-% ; *

+" + . 74KE=

/

-3 .* *

K5E

<7K5555
* 2
* B " %

*
-B"%C*.
;
? B"%C*
6
P;*7I; 0
? * 6
? ? 6 0

" *

+
"

- .
Incentives
Taxation "

C#? 4558z

4KE

Corporate tax

1 "2 74KE*

9


39
25%
R&D tax credit, giving an effective
deduction in Ireland of 37,5%
Tax landscape for entrepreneurs Finance
C#? "*
" * % + -%+. ;

9 C#?

;-;.

* "*

"?;"

;"
455IC#? <7K5555
"?;

<755555+ 457IC

C#? 2

"
"D

*= D

"

*

' =

%

= " - (@@ .

457I+ 3

<7K5555 "-".

*

KE *

"=
C#?

" 9

" 75E

C#?

-

7KE.<755555 *

*

*

=

C#?3 <NK5555"

- 9 .

0

9
;

9
Tax landscape for investors + ! "-+!"D
" .
"

"
*

<755555 2 - .
4575
40
Availability of capital Structuring for the future
? *
9

"?; "29
"

;

2

"
and incentives "

"

0

" , %-",%D . =

"

; 0

; "
!

",%*
;
"

,+
;

*

,+

+ 9 4577

0
* 2
%

">

" C#?

* 0* "

, ;
-,;.

">"
6 =
0 C#?

0 - (@@ .
,;
€650,000 Potential grants available

41
The entrepreneurial culture 3*
" B

"

0

("%;B-" %
;
B( .;"!"

-" > = P6

; ( .!

"2

*
"
"

2

; - .

;
Taxation

"
9 0
Corporate tax
=
"2

9 "

"
7JJ5"2
3

" 4575

447
&

) 1 ;

787

-
.;FKE

& ) -B1M.
- 75.

&)- "
K5.

*

(

"

"
O5E B1M

-9

"- .
.

6 6
O5E
-
.!

" "
" *6

- "6( .
" 3

B1M
42
3%
Notional return on equity increases from
FY2011 available as a deduction
Incentives
=

-*
"

B1M

-C#?.
45774574
.1
;
*

455O 455O4575*
-
9I5E =J5E

58E5FE

C#?

2.
0 -%"*?;.* 455O4575D
" 45774574 1 "
- . B
I5E %"*?;" B

C#?

-

I5E .

Finance
" C#?
,

Grants and other support

"2 ,"2

(
7 ?
;
" Tax landscape for investors
4 G-

; 455O

.

%"*?;

I P =
"
!$4577

" - .
" ;

0

* =
- 45779457I
9 -

*
IE. =
P;* ;

=

I7?4575 .

*
6 0

= Tax landscape for entrepreneurs

" 2 3 (
"
-
" ,
3, 4FKE.D C -,"C.D ,

9
-,?+.D " ,

-"C;>. IJE ?-,+.;


43
221
Companies operating as ‘pure
biotechnology’ companies in Italy

.

"2

9

-B
Availability of capital "
+ 9
B
.
,"C4574
? 7JO4@455N '

+ !>
-
455F457I.<7JIK >
"
74

0
"

Regulatory environment JKE
and incentives -"C+.B
3"C;>

"-">.

MFO
6
0
455N ?

3
JO@88@6
4FKE"C+*
;
">

1 " "2

0C#?

">
*

$ 3
; 2
"> 3

9 0 "C+"C;>"

">

Structuring for the future 32

"2

1

"-

.
,B

-

44
*
The entrepreneurial culture Taxation
B * B

Corporate tax
+ 6

G 9 C

?

+

45E
-+
&" +.6 +
%)$
-+ 6 +6.
B
B

"
NFIA

* B !
";
B
-B!";. ? ,
; ;
" C 3
*
B9

- (@@.
B

NL Agency B
BM;
(
!4577
BM
6 6
D7775BMP?
4KE;45E
" DBM" DBM D
<455555 ;
BM>1*

KE

-">.
"
+ C

BM;
-.=

;% ? !
-; 3.

BM;
- (@@
.
-;>;.
5%
Corporate tax rate applied to income
under Innovation Box regime

45
;>;

2
5E
!
; B

-= Incentives
=
3
" B
5E.

B 3
?

-;*C.

*
=

- .
;

+
% 0

& )

;*C "

0
" "

;
;>;;*C %*

;>;

9 -
;*C -C#?.

=
* " %
B B .
>%

"
* L455F

KE " %7L4575

9
" " %
& )
=
">
*

" KE
O5E
7KE
* KE

!L455F
9

? *

9
?
" " %

?

G
=
,
=
75;
+ KE * " %
75E
9 * >%
"

=

!
>9+ ? *

KE
; " %
?
45E

46
" "
? ;
%

= ( ?
4574* 3
7 ;

C?; :
- . ? - . * C#?-'%+1.
: C#?*

- .

9
" %
C#?
4*
C#?*

C#?*
I7?455N

*

4*
C#? 3
C#? - *
, ; . K5E <445555 Tax landscape for investors

I7
C#?7OE
!

?455F "4574

B
<77555578E
I

C#? !4574 C#?
0

"
C #?? -! %

*

-C?;. C?; !%".3

= 6C#?=

85E =

;*C;>;
6= 3

3

'
4KE

75E
0%
Dutch withholding tax on
interest and royalties

47
*
99 45

3 9
=

9
' ? 3*
!4574 <73

Regulatory Environment

Finance and incentives
M
* B 3
-
9

Tax landscape for entrepreneur
. 3

">"

*

B ;
International innovation
(
*

Ź ;4KE * Structuring for the future
Ź B

<FK55553
*

=
-

. *
* B

Ź B?

C#?3
*

?

Ź B?

=

?
*

Ź B *
B KE
Ź ;

&
-%0 6 " " )6

;
, * + ; + =

[* .D 0 6
-6L+
+.
0
9

6 C[;

- . 6
0

6 Energy Research Grants (EOS)
*
* ? G

;*C;>; = " %

" 0C#?
"

*
C >
">
B

* 9 * ">
B 9

?
"
B
48
The entrepreneurial culture Incentives
Norway " B

9
- 3
.
;
&+)

C#?
- .
;

Taxation 3
C 6B-B!C.
Corporate tax ! 4577
*
4OE/ 7OE-45E
M 9 9 0.
C#?
B1[KK
;
&+)
C#?B1[77
-C#?.
C#?3*
- .
B1[44

;

9

*
C#?
0
! *

C#? 0

B

B

;

9B

=

!

;3

B1[7K555 0
-'*. =

! ;
6 9
C#? 3 - .

0
;
->.
3 BIE 3
C#?3 4OE

0 5O8E
K5E
;
B

B

* =
C#?
;
34OE

49
IE

Finance ;
5O8E

*

B

" B B'*

J5E C 6 B " -

9 ?6 B .
" B
- 3
. ;2

9 B!
?

'* B
;B

JFE Availability of capital

"

3 B *

B

9 >
75E
B

9 3 6

6

B

B

-">.

34OE Structuring for the future +
=
;
B
;

B

">
*
755E

">B
JFE
;
;2
B

* 3 * B
0 * '*
'* 9
0 ">

9

;

-
.
NOK2.2m Maximum additional R&D tax credit available per annum

under “Skattefunn” tax incentive regime
50
14
Number of special economic zones where
exemptions from corporate income tax are available
The entrepreneurial culture *
> * > G

, 9;+
>
-,;+>."

'

C#?
2*
*
9 0 D
3D
>MBI455
>MB7KN553*
D

"

> "
!
";
->;" "^.
, -,.G

'
,
,;+>

& )

+ G

Maximum support level:
>MB85

4K53+
K5EY
-C#?.
85EY
>MBI
I5EY

IK3

Y> (

945
>MB7N5K53 975 9 0
; +,

;
"
*
3
("9 -

&
)
.
>MB8
9 -

3

.

;
;

!

'I5E

K5E; 7553;
(

=4574 C#?

51
PLN4m
Maximum cash grant available for
SMEs as technology credits
The Innotech Program

In-tech Hi-tech
Ź +

3 Ź +
3

(
C#?

Ź C#?
Ź

Maximum level of aid
C#?3( C#?3(
Ź , >MB75 Ź , >MBK
Ź " ( Ź " (
Ź K5E
Ź K5E

Ź * ( Ź * (
; , ; ,

+ 45E 7KE O5E + 45E 7KE O5E
, 75E 7KE FKE , 75E 7KE FKE
M
9 7KE NKE Ź ?(
Ź ?( Ź 4KE

Ź 4KE
Ź * (
Ź * ( ; ,

; ,
+ 45E 7KE N5E
+ 45E 7KE N5E , 75E 7KE K5E
, 75E 7KE K5E
M
9 7KE 85E
Ź 755E3

Applications
Ź ; * Ź ;
LL-4574 * LL-4574
457I.* ( 457I.
D
Ź * ( D

* +,
* +,* 3

>
" 3 9 * 3

> 9 * *
3 3
52
>MB4

753 > > * =
*
C#?

3 3>MB855555 C#?1
I5E C#? !

I5EK5E-
*
.
<455555

"
Taxation *
C#?

Corporate law

> <74
;

45E

C#?-
K5E .;
0 0 , ;

* 3 78 0 >
; Tax landscape for entrepreneurs

0
;> 7N

* *
*
7JE*

* 3
0 - +
(
4545
4545

2C#?

.; 0 ! ,0

"

"
* 74

0
Under the program, the total value of a
3 = C ?6+
<K5* C#? &
<FK" 3 )6 45E
M0P ,0 M 2
> ' ,0[39

53
The entrepreneurial culture (

>
; >
G
455F

>

>

"C6

6
*

>

>
3"C64KE

6

3"C6
>

"

85 ;"C675E7KE
4557455N
' G-
-C#?.
.+ 3

7KE
;

9
4KE
"C6 <4
, C#?
>
, ?

0

>
!4575

Taxation
Incentives
Corporate tax %

(
">
-"C6.
9 Ź +
"!"?-
C#?.

>

3"C64KE C#?

32,5%
SIFIDE tax credit of R&D expenses performed
54
20%
RFAI tax credit of relevant investment performed
=
3
C#?
3D

(I4KE
3D
Finance

D K5E *
2

3

-455F
K5E
457I. B +

C!-B+C!.B

Tax landscape for investors >

<7K " -

9 0 -+,.
Ź C
!;" 45E-<K
- .

-
.75E-
*
.
(
<K. "

Ź +
"#?*
=
"
>

C!;" N5 ;
-C#*?.

3*

3 >9+ ? -

C#*?
."
FKE

3
-.

3

B Ź +
""{|

"

9
* 3
>

- .
* 9

6

=
3 -. *
- .
I7?4545 /45E
- .
*= 3

<K = &
)

+""{|

;
KKE 2

>

3

3 =
FKE

= 9
>
* 9

75E 3
3
45E
?
-

Ź +
"z {|>,
3.D

55
+, " "

0

0 B
D
3

;
"

>

% ; 6 -6;.

3

"

6 -+>P.

>3 +" = >

"{|

*
>
+

=
+>P =

>

3
% +"!"?C!;"

" G
4575
455J

+ 9
9
0, >

>

90,
* 0
75%
8E- 4574.
KE- 457I4545.*

-
>
.

SI&DT - rate that may be attainable on
*
relevant global investment

3

, ;C

/ 3
56

+ ? +

455J

* JIE

4K5

JKE

* "B
"455J +

4KE
75JK 7KE

IJJ

; "455J C#?
78ON8O
<8OK K8E

<KI7K4 *
%
- + -OJKE.

. +

<FF777KE 2-NFOE.

? -48OE.1 -NIE.

0
9
(7N4E - 7E.

I5OE

* (

Ź

455K
-4IEIKE . Ź
*
Ź
9

(

Taxation

*

Corporate tax

6

+

*

FE
C#?
I5E+9 9 0
KE

4KE
C#? "
<74545487
I5E

C#?

74E1
* 2
-OKE
.* + G;;>
7
" 4575;+%"1;BB;MC>1C*

57
3 ;
+ 6"*

-C#?.

3
*

"*
C#?
+

7O!
-74E.

C
7K
"*
?-C#?.3*

" -"*.3" * NKE
=
Incentives 3C#?"*

*

+,
" C#?

C#? * -"*.

6= =
"+ %
C#?@"* 9 +
;
+%;B

=

L455O
9 +,&
)
* +

G
=

0

1
C
;
=
6}, + = 6
C#?"*
* 3

45E>"*= C#?
= "
C#?
*
4KE
*
<8555

-C#?"*.IKE

84E
1
; 7FE
-C#?.
+ 2

=
9 0

K5E
OE -

+9

. C#?

+%;B

%
* 75E

*
6}

, "

* 7K

!
45E =
7K
3

<8555
58
Patent boxes 455F9457I'

<K5K47 >

M7N@455F
8

+
" 6

*

%
"

!7I455O B
6

;
=

(

Ź >

~
L455O
->"?.(0

93
4I6"*MK5E

<485555

Ź M
96?*" ~
=

-">.

~
( 0

* K5E

2

Ź " B1*6 ~
~
z

~
( 0

- .

*

C#?
Finance and Incentives

% * "

0 *

+ 6G-

."
+ !>
-!>F.

3*
?

59
0%
Tax on unlisted participation
held by companies
The entrepreneurial culture 0

9
+ *

9
+
"
9

;M,"!]
"

;M," " 2
9 3

*

9
9 0 -+,2.

$ =
;M,"+[4K5555 " 2
9

* =

+[4K5555 "

= ;M,"
9
+9

C ; (

1 =

+ "

=
P"BB1P; + G
*

;
" +"

+2

P

"
P"BB1P;2

C#?3
+,

9
*

;
C#?

P"BB1P;2
9 "
9

9

+
7JFJ"
! (

"

C
" P
+
60
Taxation Incentives ;
2 +
6C#? "4KE
Corporate tax

+
+ *;*
*

2 ,

+
(
+
9
D

;
D
+
*

4NIE

2 *

* L74574
+[OO555

* 9 "
*

= (

+
0 Ź '

, *

+

C#? Ź =
+
- , 4577
3

.G +
*
+

C#? Ź Work at the top management level or

3 *
0 +

+

+
= - +

+ 6

G
3
457I 9 9 0+.
SEK250,000
Security free loan available to SMEs from
ALMI Företagspartner

61

;

+

I5KOE
are normally exempt from tax under the , +

+ !]
s

9 6*"
*
9 +*

*45KOE *
" 4KE ;9

K5E
+
!

I5E> " 2

9 -
B Regulatory Environment
. and incentives
"4577 G 3!
*

;

- .

*

=

* 6* - . * + >C
1
6 -+!]
s. I5E

&*
) L* *
+6

4KE

+$
*
45E

- + >
+ C
12
.
1 6=
* , >;

*

-+ .*
99

9
+
L7457I

Finance >(
Tax landscape for entrepreneurs "

* 6
-
!>F
+ 6
+ ;
-[".6
0
.*
+
62
+ ;

+

16?

= +

6

?

C(
9 ;
+

Exemption for teachers +
*

+ >
-M;7J8J(I8K.
= *

2
*

'

2 >
*
7 )

9 +

+ =

)*
B +

0 "> + 0

@3 C#?
"+ ;+

C#?
+ +


; +

">

+

&
9) 0
25%

;

C#?

foreign experts/researchers/key personnel
can be exempt from Swedish tax

63
The entrepreneurial culture ; 6 2
+ 0 + 0

*

6 *

" -6*".C#?
3
-C#?. 9 6*"
%@%^ 0

G@P;

C#?"

%^ GM 6*"(
" 9
7 ,9 C#?3D
+ 0
* G 4 6 9
2 D
C#?
I [

* + % ;
2 -
. +
C#?
"+ 0
3

4N >3

9

3

M + 0

+ 0 6*"2P
9
- . 9
99

*

$

B
9
9

* 6*"

10 years
Potential length of cantonal taxa holidays
9 > 9
C#?[**+,

9

9
64
12% - 25%
Combined effective tax rate depending on location,
without accessing preferential tax concessions
" + 75E Incentives
6!7.*
%

(

C[;C;B!>F

-*>. 1) Tax holidays
M

! 75

are free to grant full or partial relief from
Taxation
-

.M
9

Corporate tax
+ 0
*

"+ 0 3
0
"=

=
*
0 3
74E

4KE
M

! ;

& C;)"
- . -
(755ED
= (F5ED
(F5E. 75*

?

9 -+M. 9

;

-?%.; 3

& )"

85E
9 "

2= C
-?%.45E-+M.+
9 *
5557E5KE

-

+
9 . =

P
-P;*.
'
2) Provisions
OE4KE
-

!

.IKEB
0 9

9
6

"
;

!

=

9C#?
3

75E
- + 0
6!7>
= 75E

.
P;*

C

3 6 9
=
+
- =

65
3) Capitalization of R&D expenses 1 *
C#?
* 3
3 0 -
*
0 " .
7JE98KE +B+!
C#? 0
" =
6!F55

7JK4

"
+B+!

! 9

6!7O555 * +B+!

-

. + 0
Tax landscape for investors +

1 "

"+ 0

*
+ "

- * 6 29
Availability for capital
. 2 "
+ 0
+ 75IE

75E ; "
* -. + :
C

:

*

=
+
= 9
+
+

3
9 - .

-

.; *
4558

-66>.

Regulatory Environment
4577
and incentives
I7?7JJN *

Finance + 0

!
- * + B + !

+ .* -+B+!. + 02

* +B+!

F455
*

O5
IK
'
*
+ - .
"+ 0
*
+
77KE -">.
66

= +
+ !

O5E
-
.

0

;+

* 9*

= "
+ B + ! %

- .
OE974E

* 6

C#?
*
"

C#?- 9 ." ;

D

6B
+ 0
& )
" + 0 D
">C#?

+
!>
C

B
*
?

6 +
" *
* C - D
K5E 74
D
.
1
0 6

?"
Structuring for the future 8KEJE

= "

C#?
; 3

"+ 0 = -.
OOE
= *

; 0 ;

75

*
=

; *

7,200
Number of researchers supported annually by the
Swiss National Science Foundation

67
£10m
Lifetime limit of concessional tax relief
for individuals on qualifying assets
*
The entrepreneurial culture Taxation
[
* [G

Corporate tax
-
.% M * [

G2

"
*

4KE
7; 4574 G

0
4IE
-
.+ ; 4578
%
*
,

4577?
B "
[ +(

? 6 > ,
G
1 6 C "
= G
-
.
Tax losses
* *
+
% [2 " [

"

9

B

9 0
* *
* [

+
%

G

C#?[
*>

-
.
%
* C
G !

' 78 [
FKE
2
4578

"
Incentives

* [

;
3
-C#?.

C>-, .

KJ
7I5E=

^ 3 "

36
0 9 0 -+,.

* 455E
-
. !; 4574 44KE
68
200%
Potential rate of tax relief for SMEs on
certain R&D expenditure
*

;

6 B

0 *


0
= B +
! -
.
=
1 (
+ +

Ź @ !
=

Ź
@CG!

= !

2 Ź

75E-
*

4OE.
= 2
75=
Regulatory Environment 0

* =

-KE.
and incentives

;
C#?
=
[2

0

"+ P

6 * " [

*

C
[2

+

2
*

*
2 K

75 [ M 9

C#?

0*
* G -">.

Finance B 16 C
; % "-B16C"D . ;

*

*

* [
>

0
B16C" % 75E

:

6 *
-
@.
=
">*
M >
B16C"
">


69
70
Part B:
[
through the


71
Importance of understanding

0
= ;
customs and international trade 99
considerations for carrying out

3
clinical trials on a global basis !

6
1 -

9 =

* .
*

9 - 9

.
= 9

6

,
; -

" 9

.

*

*

D

9

&9)

D +

0

= :

P;*
1 =
>

= 6
= * -
.6
+
9

'
3

duty in many of the favored emerging market

" 6 C

%0 * =

IE94FE' Focus on: customs valuation
P;* 755 Background on key customs and *

international trade considerations
45E9I5E and international trade environment,
; -6*,.

P;*
&9

0)

6*,

;

! ?

6*,

C#?
P;*'

72
? =

->#G.+
99

"

C#?
>#G
*

Ź , K(&? )
*

Ź Value(

0

'*1
0 -'*1.=
Ź , N(*
Ź Identify and minimize(
& )
*
/
=

= - , 7
"

, 4.%

Ź Recover( 0
C#? -
6C1.+

3

* '*1P

;
( Summary of major tax

Ź , 7(&* ) considerations for exploitation of

Intellectual Property
*
-
= 1 -">.

" 2
.

Ź , 4(P & )& )
&
) "
- =*
">

9

*
. "

Ź , I(P
Key messages
9
&
):

">
6*, +

- !
Ź , 8(&6)

.* 9 ">


73
6 = C#? ; *

= +

(
"

7M

C#?*

;

D

D

& )
9
* C#?
4! 3 -LP.

Other key questions to consider:
;

H
*

H' I

( 0
9&
)
9
9

*

=
H
Some tax considerations
Table 4: Structure
IP location
Tax rate & incentives
Exploit -
SME Licence
Tax treaty network
or JV
Patent box
IP Transfer pricing
Supply chain
Sale
Market access, regulatory
74
The recent Ernst & Young 2010 Global Transfer

Ź *
(

Ź ;

Ź M
= ,

Ź

Ź *

Ź *

,

-

0 .
' 9
0
(

&
) 9 ">

+ *
">
(
Ź > (

International tax 3*

H
% 9

3 Ź ,
">(

C#? ;
H 9
=

Ź ;(

*
" 16?

Transfer pricing ;
6

"

;

C#?

3

*

C#?

* 0
">

*

"> ; -O975.;
9

9

=

2 3

3 , C#?
9

">
+

* 3

3

>

"

0

1
">

0

0
99

3
*
!

3


75
Part C:
;
and the outlook

in Europe
76
Pharma – the current ;

cornerstone of
*
biotechnology in Europe ;
> C
,; ! 2
;
6

,+

+
0 "

%

"

The pipeline for biopharmaceuticals

8

*

/ " 4NE+
Contract research organizations
9

(CROs) on the rise

74E

;

4575, C F
0 * 9
6C1;
?

= ( 7 9 0

6C1

O"

=

K
9 9
9
! 455K I4J * 6C1

9
0

+K5+455* """* Looking to emerging markets
485 +K5
' ",+

* =4FE
+
4
6C1*

457K

+

N

D ;
The role of social media

+7K8

D The Wall Street Journal

I"
; 7OE

* +8OF IFE
45EI5E 4545 J

7
&1+
% )M + ? BJ+4577
4
"
I
"
8
"
K
&' 6C 1
0 )> 814577
N
&+6C1,&45 457F)> * 7F14577
F
&+(4N ), B7J14577
O
&>
G
)> * 4714577
J
&'

,C+> H)> 4514577

77
, Table 1: Key indicators of growth in primary emerging markets 74

3 Emerging
Reasons for growth

market

+ Brazil Ź '2 9
Ź +

457K

Ź > Ź Growing population
85E 2

+457O 4575
75

Ź > J5E
J5E
population
4545 Russia Ź '2 9
Ź "

" Ź >
+7ON Ź
",+ 7N

4577
&

) *
Ź "
9
6 %0 " C *>
P0;
" + India Ź '29
Ź C

; * C
population
Ź
> P Ź 75E

% Ź !

7IE7NE457K China Ź M

Ź C

*

Ź '2
Ź

457777 Ź * 9
Ź G

Ź >3
4KE Ź C 0
4577
A focus on health outcomes B^6
* [ B "
;
6 -B"6.

7JJJ

9
:
= 3
-6;.
2
-z;M$.:

B

+ -B+.
'

"+ ?>
6; 7I
%;
-*MP. 06;
6;

1

9 =

%
! "
* 3 B B >

6; ; 7JJI G"
75
+#>2&"+ (> )4L45777I
77
"
74
" 78:7K
7I
&,
P(> * > )1 *?+47,4577K
78
; M ; Ź G = 4K553
78

47*
[

6; +
H K55344?

+
4KE

; 6;

0

4I
-6C. 6;

"
>
75 9 6;

!

/
; CC ;
;

455J 0+776C7K 9 ;

* <IK 486
6C

C#?

!
6;

C

[9 =

G+ [ -G+[.
!

9 9 ,M

7O !7
*

45

Manufacturing and supply chains ,M2
G+[

+ * & )

,M2
3 "

4K

7N

*
6;

6

/

*

6; = ( 7F

G2%
Ź "
"4557+9L # 4577

H L 6

75553 %
Ź !
H
6 7J"4577, +

Ź ' H 78E

%
"
4N%
Ź

45+ 02B /
H
78
"
7K
&6 C
> " )> PG+P4OB75714575
7N
&' 6 C H)+? #+ ;
C z
7F
&,
P(> * > )1 *?+47,4577O
7O
" J
7J
&L#L +67555L)! > *+7NL4577( (@@ @@339 999755593@457795N97N
45
&+> L#L % )The Wall Street Journal,L C7NL4577(
(@@ 3@ @+%755578485K4F54I587ON858KFNIOF845O77447KIO
47
&69B 64K55LG:>)C6 %4K+4577(
(@@@ @4577@5J@4K@ 9 +MKF[154Q45775J4K +MKF[154Q45775J4K
44
&+ >*B M6(4K55)! > *+4N+4577(
(@@ @@ 999 9994K55@457795J94N
4I
&?6K55L C
)C% %O+4577( (@@@ @4577@5J@5O@99 +B7FOF7*G45775J5O
48
&' +
> +6 )> MG?+" (
(@@ @F7KJ@@ 9@ 9
9 99 9 9 @
4K
&,M; *
G+[C )"> > *7N+4577( (@@ @@7NFI7F@
99 9
4N
&%6C
K85L 6;)! > M 0L 4F,4577( (@@ @@99
9K85939@457795K94F

79
4F"4575
>

N5E

+8ON4O 455N1
+
, 3
+74 455F

0B$ +OI5O 4575

+ONI457N6;GC75E4J =>045E + ; 6 6
,
+

2 455N"455O, I7
78E +2+
9
* 9

/ >
75E' -

>0 455J. 7455
>

,>0

+

77E +

K55 G"
M +!

?
; -!?;.

$
,

-;>".

* + = *

" " I5

2

9
0

CI5* !?;

M ^+ 7K

; +
0 0?
+* !?;
4574FK555

0

"
+4NE 455F

!?;

+ ;

6

"

+9
A shift in marketing and selling 6
>
+JI 455J+K 4575

*
7JJ54555

3

+445 4575

0

/

>> >0
%7JJN455K + 2

+I88
>

4575

755555?

>

+I7O4K57O9
4NEC

*

* 6

*

"IFE

4F
"
4O
&6> ,
C >

(G,),C 7+4577(
(@@ @%669C 9IF8@69> 9,
9C 9>

9NKKNIN4@
4J
"
I5
? 9+
3 C L455O
I7
&6 +!6,!
? )> + 74+4577(
(@@ @4577@5J@ 9999
9 @
80
*
0 ->>1.D45E
*

0 -,1.D
3
C 75E 99 ->1+.D

,

> >>1 I9KE
+ 2
IN

,12
"

IF
* I8
* (

0
,

Ź >

Ź C

+
,
Ź > 0

Ź ?

C
*
Ź >

"

Pressures on pricing and

*
reimbursement (
* *
Ź > 9
+G *

Ź ! @

D 0 Ź P

D
Ź >

2?

>

Ź C 9

G
9
9 " Ź 1*6

+

Ź > @
KKE

Ź %

G
0

I4
Ź G 9
;KJE+

"
G

; L
455JII1 JOE

IK

"
99
1

N5E

!
7

I4
& +(' H)" L![
>N; 455J
II
& %)4575;+L[ ! ! 8
I8
+#>2&"+ (> )IL45757O:7J
IK
+#>2&"+ (> )4L45774O
IN
" 74
IF
? &> [*4577: +?
C
1 ), 4577KO

81
Figure 1: Pricing and reimbursement pressuresIO
Price cuts Reimbursement cuts US healthcare reform

Ź 4575 L Ź !

Ź C ,
; !"G 775

7K7E4I7E
6 4575 Ź K5E ,

Ź %

Ź C >?

Ź C "

Pricing and reimbursement pressures
Growing price negotiation Greater use of pharmacoeconomics

Ź 6 Ź +
+
Ź "9

reform
Ź G

= Ź "z'"G G
L4577 9

Ź P9

4578 [ Ź !

9
negotiation

IO
" KJ
82
C Ź
%

0

9 69

" / 2

9
0 2

9

IJ* 3 *

9

>

* +

6;

0
!?;
+

=

;

* 0

85

0

*

9

+ 87"
*

9

/

*

(

Ź * 0
2 C#?

!
2

>

->%,.
9
*
9

;

7JJ5
= >%,

* G

=
>%,2

IJ
+#>2&"+ (> )IL4575I4
85
"
87
& 96"' +> )The Wall Street Journal,F!4554

83
Outlook for the
% and appropriate regulatory framework
*? >

biotechnology industry >?

=
in Europe

> 6
;
!
" / *

P 9> *3 2"

>6C
0
;
! > 0;

9

0
*
*
9

,+

Industrial biotechnology

6
2
1

4574;

' 9

, "

+
+

"
[
*

2 6

:
*
"

,+
<4
*

, 4577
44"
C#?

* 9

0 M

9

2

:

= 3
:

, ;

-,;. =
9

Healthcare biotechnology *

6K5E

"

F5E

;

K5*
;

4574

*

0

; " 26;
> -6;>.
457I945D 6
84
+
!>

45789

45 045452D

* B 0

> 4575

;

Agricultural biotechnology *

*

G,

+

"
D

-G,. 6

D
(,1BO75

0

;/ "
' 6 2 J5G,
+
!C
" +" 2

"

%

0
4545 G,

D D

+
-C?". 0 +
4545

C "
" "

+
G,;I5

!>

7I 04
<4<8F 04545
"

"
B + ; "

0

*
*
%
+
!4574
*

C?"3

85
Acknowledgements
Jürg Zürcher 87KO4OJO85I Neil Byrne IKI74474IF5
Biotechnology 3
0 Global Life
Leader EMEIA Sciences Tax
Leader
#$

+ 0 #$

"
Domenico IJNOKKNFIOI Dick I7OO85F787J

Borzumato 0 Hoogenberg

#$
#$

" B
Daniela 8I7477F574NF Narve Lovo 8F48554JIJ

Demschner
#$

#$
Norway
;
Kurt Van der I44FF8J4O7 Bartosz 8O44KKFFJJF

Voorde 0 0 0
#$
#$

Belgium >
Malene 8KIKOF4JF7 Joao Sousa IK747FJ8JI5K

Levinsky 3
#$

#$
>

?
Philippe II7KKN77545 Francisco IJ4OK7888J

Paul-Boncour 99 Hamilton 9
Pereira
#$

! #$

>

Reinhard 8JOJ78II77I5FJ Marta I8J7KF4FNNN

Lange
Rodriguez
0
Viciana
#$

Germany #$

+
Robert IN78K7O4N4 Catarina 8NOK45KJ7I5

Heinczinger 0
Dreijer

#$
#$

+
Gyorgy IN78K7ON5K Markus Frank 87KO4ONI7OJ

Szekely

0 Huber 9
#$
#$

+ 0
Paul Fitzgerald Mike Grice

IKI74474K7F 8845FJK75ON4
#$
#$

0

" [
Karen Holden Tracee Fultz

747K88O4N4I 7474FFI4NJ5
#$
#$
+ + 0

; ;
86
Thomas Saylor Nathalie Moll Rosalind Travers
% 6 +, +G% 6 #
> B ;
M 1

87
Glossary of terms
Accounting period
* 2
2
*
2
Bioeconomy Strategy
;
6 4574

" 9
9 *
9

Capital allowances
- .
=

= ;
Carry on business
;

Chargeable gain
"

- 9
."

Clinical phase
C
(
Phase 1:

Phase 2:

7 "

Phase 3:

Common Agricultural Policy (CAP)

* 6;
>
2

=

* 6;>
457I

88
Computation
*

Corporation tax
;

Credit, tax
*
- .
"

Declaration
* 2

Deduction
; *

*

Depreciating assets
;

N5 [ =

European Medicines Agency (EMA)

* , ;

M*

EU 2020 Initiative
4545 2

6
3 9 @

9 4545!

G

Health Technology Assessment (HTA)

*; 9

Horizon 2020
04545
" 4545
/

2
C
4578
4545 <O5
2

3

89
HTA authority
;

-*;.

-
[2B " 6
B"6.
Indication
*

Intangible assets
"3

=
Market access
;

Marketing authorisation application (MAA)

;
Orphan disease
;

Permanent establishment
;
- .
Pivotal clinical trial

;
&9)

-*;.
Pricing and Reimbursement (P&R)

>

C
-
.
+

Pre-clinical
* 9

Rates (of corporation tax)

* [

2
( 9 9
*

90
Relief
; *

*

Research and Development (R&D)

" & )9

9

=

Small and Medium Size Enterprise (SME)

" +, 4K5
<K5
<8I
Tax credit
C
- .

Tax liability
*
Transfer pricing
C
3

Tax treaty network

,

*

91
92
Ernst & Young
Assurance | Tax | Transactions | Advisory
About Ernst & Young

Ernst & Young is a global leader in assurance, tax,
transaction and advisory services. Worldwide, our
152,000 people are united by our shared values and
an unwavering commitment to quality. We make a EuropaBio is the European Association for Bioindustries,
difference by helping our people, our clients and our bringing together bioscience companies from all fields
of research and development, testing, manufacturing
wider communities achieve their potential.
and distribution of biotechnology products. It has
54 corporate members, 6 associate members, 2
Ernst & Young refers to the global organization of
BioRegions and 18 National Biotechnology Associations
member firms of Ernst & Young Global Limited, each representing some 1800 small and medium sized
of which is a separate legal entity. enterprises
Ernst & Young Global Limited, a UK company limited
by guarantee, does not provide services to clients.
For more information about our organization, please
visit www.ey.com.
Life sciences companies — from emerging to

multinational — are facing challenging times as
access to health care takes on new importance.
Stakeholder expectations are shifting, the costs
and risks of product development are increasing,
alternative business models are manifesting, and
collaborations are becoming more complex. At the
same time, players from other sectors are entering
the field, contributing to a new ecosystem for
delivering health care. New measures of success
are also emerging as the sector begins to focus on
improving a patient’s “health outcome,” and not just
on units of a product sold. Our Global Life Sciences
Center brings together a worldwide network of over
7,000 sector-focused assurance, tax, transaction
and advisory professionals to anticipate trends,
identify implications and develop points of view on
how to respond to the critical sector issues. We can
help you navigate your way forward and achieve
success in the new health ecosystem.
© 2012 EYGM Limited.

All Rights Reserved.
This publication contains information in summary form and is
therefore intended for general guidance only. It is not intended
to be a substitute for detailed research or the exercise of
professional judgment. Neither EYGM Limited nor any other
member of the global Ernst & Young organization can accept
any responsibility for loss occasioned to any person acting
or refraining from action as a result of any material in this
publication. On any specific matter, reference should be made to
the appropriate advisor.
The opinions of third parties set out in this publication are not
necessarily the opinions of the global Ernst & Young organization
or its member firms. Moreover, they should be viewed in the
context of the time they were expressed.
xxxx.indd (UK) 03/12.
No expiry

EY What Europe Has To Offer Biotechnology Companies

Caricato da

Informazioni sul documento

Titolo originale

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

EY What Europe Has To Offer Biotechnology Companies

Caricato da

Copyright:

Formati disponibili

What Europe has to

Biotechnology regulatory overview 11

Part A: The establishment of a company:

Part B: Key tax considerations through the

Part C: An industry study and the outlook

What Europe has to offer biotechnology companies 

      

 %    &'         

            1    

(@@@ @ @@457454A 

What Europe has to offer biotechnology companies 

What Europe has to offer biotechnology

"      0 4545  

+        

       

What Europe has to offer biotechnology companies 

*        

What Europe has to offer biotechnology companies 

       

   

What Europe has to offer biotechnology companies 

Ź ;  ;   ;   : 7KE Ź '     0   

G        Ź '   

What Europe has to offer biotechnology companies 

"        

What Europe has to offer biotechnology companies 

Total 4 '    ! +  ;  

+( 6  L 4577

What Europe has to offer biotechnology companies 

    755E \ <8O

     *    

 C  "  

Ź *    G,,    

What Europe has to offer biotechnology companies 

*       G,, =  44

*  6        

*  6          

What Europe has to offer biotechnology companies 

The United Kingdom 68

;  *    

What Europe has to offer biotechnology companies 

    45E     NE         

    FKE     

What Europe has to offer biotechnology companies 

What Europe has to offer biotechnology companies 

            

What Europe has to offer biotechnology companies 

Structuring for the future

? " ?   9    

The entrepreneurial culture <FNI555 

! *      4I555 

What Europe has to offer biotechnology companies 

    

Tax landscape for entrepreneurs

Tax credit on eligible R&D expenditure

What Europe has to offer biotechnology companies 

Germany        

;      

 FE  7OE !      !    

 G   .D       G

        

What Europe has to offer biotechnology companies 

9          -  9 0  

What Europe has to offer biotechnology companies

% &'

1

(@@@ @ @@457454A

What Europe has to offer biotechnology companies

" 04545

+

What Europe has to offer biotechnology companies

*

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

Ź ; ; ; :7KE Ź ' 0

G Ź '

What Europe has to offer biotechnology companies

"

What Europe has to offer biotechnology companies

Total 4' !+;

+(6 L4577

What Europe has to offer biotechnology companies

755E\<8O

*

C "

Ź * G,,

What Europe has to offer biotechnology companies

* G,,= 44

* 6

* 6

What Europe has to offer biotechnology companies

; *

What Europe has to offer biotechnology companies

45E NE

FKE

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

? "?9

The entrepreneurial culture <FNI555

! * 4I555

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

Germany

;

FE7OE! !

G .D G

What Europe has to offer biotechnology companies

9 - 9 0

Availability of capital

&* G%

What Europe has to offer biotechnology companies

The entrepreneurial culture 9

" "

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

" B

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

Norway " B

What Europe has to offer biotechnology companies

The entrepreneurial culture *

> * > G

+ G

; +,

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

% +"!"?C!;"

+ ? +

* JIE

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

The entrepreneurial culture 0

+ *

What Europe has to offer biotechnology companies

What Europe has to offer biotechnology companies

+ 0 + 0

* 6*"

What Europe has to offer biotechnology companies

= *

What Europe has to offer biotechnology companies